CYSTIC FIBROSIS – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2021-11-05

SP-101, an investigational inhaled gene therapy for cystic fibrosis, shows potential in animal study

Treatment with SP-101, an investigational gene therapy that Spirovant Sciences is developing for people with cystic fibrosis (CF) who are unable to benefit from current treatments, effectively increased CFTR gene activity in a ferret model of the disease, the company reported. Katherine Excoffon, PhD, Spirovant’s vice president of research, presented the data at the 2021 North American Cystic Fibrosis Conference (NACFC). Her

FDA approves new breakthrough therapy for cystic fibrosis

Treatment approved for approximately 90% of patients with cystic fibrosis, many of whom had no approved therapeutic options Source FDA The U.S. Food and Drug Administration today approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation. Trikafta is approved for patients 12 years and older

Thirty patient deaths tied to cystic fibrosis drug following FDA database of side effects

Thirty patients have died after taking Symdeko, a Vertex Pharmaceuticals treatment for cystic fibrosis, according to a government database. The deaths, reported to the Food and Drug Administration’s database of side effects, are tied to Symdeko, a Vertex medicine approved last year. Reports to the database are commonly submitted by health care professionals and often contain

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Category CYSTIC FIBROSIS

SP-101, an investigational inhaled gene therapy for cystic fibrosis, shows potential in animal study

FDA approves new breakthrough therapy for cystic fibrosis

Thirty patient deaths tied to cystic fibrosis drug following FDA database of side effects